What question did this study set out to answer?

To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.

synapse

⌘+K

April 15, 2026Open Access

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

Puntos clave

To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.
Conducted a retrospective multi-center cohort study
Analyzed treatment data of Taiwanese PDAC patients
Assessed efficacy and tolerability associated with various initial dose intensities.
An initial relative dose intensity of 70-90% for irinotecan and oxaliplatin was optimal.
Patients experienced improved efficacy and tolerability at this dose range.

Resumen

The initial RDI of 70-90% for irinotecan and oxaliplatin may optimize both efficacy and tolerability in Taiwanese PDAC patients treated with FOLFIRINOX.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Ho et al. (Wed,) studied this question.

synapsesocial.com/papers/69df2a99e4eeef8a2a6af9c3 https://doi.org/https://doi.org/10.1016/j.jfma.2026.04.039

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP

2007 · 172 citations